Gelonghui, April 23 | BeiGene (688235.SH) announced recently that the European Commission has granted marketing license to Baizean (tirelizumab injection) and approved it for first-line and second-line treatment of three non-small cell lung cancer (NSCLC) indications: combination paclitaxel and carboplatin or injectable paclitaxel (albumin conjugated type) and carboplatin for use in first-line treatment of adult patients with platinum-containing radiotherapy; combined with chemoplatine and chemoplatine Used for PD-L1 expression ≥ 50% and no epidermis First-line treatment for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer with positive growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations and not suitable for surgical resection or platinum-containing chemoradiotherapy; monotherapy for adult patients with locally advanced or metastatic NSCLC after previous platinum-containing medications. NSCLC patients with EGFR mutation or ALK mutation positive should have received targeted therapy before receiving tirelizumab therapy.